Statins and Solid Organ Transplantation

Authors: Gazi, I. F.; Liberopoulos, E. N.; Athyros, V. G.; Elisaf, M.; Mikhailidis, D. P.

Source: Current Pharmaceutical Design, Volume 12, Number 36, December 2006 , pp. 4771-4783(13)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome.

In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy.

Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.

Keywords: Statins; dyslipidaemia; transplantation; cardiovascular disease; atherosclerosis; rejection

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138161206779026308

Affiliations: 1: Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College of Medicine, University of London, Pond Street, London NW3 2QG, UK.

Publication date: 2006-12-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Statins and Solid Organ Transplantation

Buy & download fulltext article:

Tools

Key

Text size:

Useful pages